Literature DB >> 12884064

Characterisation of methicillin-resistant Staphylococcus aureus with reduced susceptibility to teicoplanin in Eastern France.

X Bertrand1, D Hocquet, M Thouverez, P Plésiat, D Talon.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2003        PMID： 12884064     DOI： 10.1007/s10096-003-0966-7

Source DB:  PubMed          Journal:  Eur J Clin Microbiol Infect Dis        ISSN： 0934-9723            Impact factor:   3.267


× No keyword cloud information.
  11 in total

Review 1.  The biological cost of antibiotic resistance.

Authors:  D I Andersson; B R Levin
Journal:  Curr Opin Microbiol       Date:  1999-10       Impact factor: 7.934

2.  Resistance to teicoplanin developing during treatment of methicillin-resistant Staphylococcus aureus infection.

Authors:  Ashraf A F Elsaghier; Hazel M Aucken; Jeremy M Hamilton-Miller; Stephen Shaw; Christopher C Kibbler
Journal:  J Antimicrob Chemother       Date:  2002-02       Impact factor: 5.790

3.  Clinical isolates of methicillin-resistant Staphylococcus aureus (MRSA) with reduced susceptibility to teicoplanin in Northwest England.

Authors:  I A Hassan; P R Chadwick; A P Johnson
Journal:  J Antimicrob Chemother       Date:  2001-09       Impact factor: 5.790

4.  A new UK strain of epidemic methicillin-resistant Staphylococcus aureus (EMRSA-17) resistant to multiple antibiotics.

Authors:  Hazel M Aucken; Mark Ganner; Stephen Murchan; Barry D Cookson; Alan P Johnson
Journal:  J Antimicrob Chemother       Date:  2002-08       Impact factor: 5.790

5.  First clinical isolate of vancomycin-intermediate Staphylococcus aureus in a French hospital.

Authors:  M C Ploy; C Grélaud; C Martin; L de Lumley; F Denis
Journal:  Lancet       Date:  1998-04-18       Impact factor: 79.321

6.  Dissemination in Japanese hospitals of strains of Staphylococcus aureus heterogeneously resistant to vancomycin.

Authors:  K Hiramatsu; N Aritaka; H Hanaki; S Kawasaki; Y Hosoda; S Hori; Y Fukuchi; I Kobayashi
Journal:  Lancet       Date:  1997-12-06       Impact factor: 79.321

7.  Vancomycin-resistant Staphylococcus aureus--Pennsylvania, 2002.

Authors: 
Journal:  MMWR Morb Mortal Wkly Rep       Date:  2002-10-11       Impact factor: 17.586

8.  Outbreak of methicillin-resistant Staphylococcus aureus with reduced susceptibility to glycopeptides in a Parisian hospital.

Authors:  F Guerin; A Buu-Hoï; J L Mainardi; G Kac; N Colardelle; S Vaupré; L Gutmann; I Podglajen
Journal:  J Clin Microbiol       Date:  2000-08       Impact factor: 5.948

9.  Antibiotic susceptibility and genotypic characterization of methicillin-resistant Staphylococcus aureus strains in eastern France.

Authors:  X Bertrand; M Thouverez; D Talon
Journal:  J Hosp Infect       Date:  2000-12       Impact factor: 3.926

10.  [Endemic heteroresistant glycopeptide intermediate Staphylcoccus aureus (hGISA) comprising unrelated clonal types and not associated with vancomycin therapy].

Authors:  E Lecaillon; P Gueudet; M Wooton; T R Walsh; A P Macgowan; M E Jones
Journal:  Pathol Biol (Paris)       Date:  2002-11
View more
  2 in total

Review 1.  Newer treatment options for skin and soft tissue infections.

Authors:  Murugan Raghavan; Peter K Linden
Journal:  Drugs       Date:  2004       Impact factor: 9.546

2.  A Strong Synergy Between the Thiopeptide Bacteriocin Micrococcin P1 and Rifampicin Against MRSA in a Murine Skin Infection Model.

Authors:  Kirill V Ovchinnikov; Christian Kranjec; Amar Telke; Morten Kjos; Tage Thorstensen; Siegfried Scherer; Harald Carlsen; Dzung B Diep
Journal:  Front Immunol       Date:  2021-07-02       Impact factor: 7.561
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.